Ginkgo Bioworks

Ginkgo Bioworks

Yahoo Finance • 2 days ago

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.68%, a... Full story

Yahoo Finance • 9 days ago

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.06 in the latest trading session, marking a +1% move from the prior day. This move outpaced the S&P 500's daily loss of 0.45%. Elsewhere, the Dow lost 1.21%, while the tech-heavy Nasdaq los... Full story

Yahoo Finance • 9 days ago

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Integration puts Ginkgo's biological data generation services at the heart of the industry's most prominent AI-driven drug discovery network BOSTON, September 16, 2026--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its... Full story

Yahoo Finance • last month

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • last month

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035"... Full story

Yahoo Finance • 5 months ago

Oncology Clinical Trials Research Report 2026: $20+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The oncology clinical trials market has seen substantial growth, transitioning from $14.9... Full story

Yahoo Finance • 8 months ago

Ginkgo, OpenAI Cut Protein Costs by 40%

This article first appeared on GuruFocus. Ginkgo Bioworks (NYSE:DNA) says a new AI collaboration with OpenAI is already paying off, cutting the cost of protein production in the lab by a meaningful margin. The company said it worked with... Full story

Yahoo Finance • 8 months ago

Ginkgo - OpenAI collaboration cuts costs in protein synthesis

[Collaboration concept in word tag cloud] rafal_olechowski Ginkgo Bioworks Holdings (DNA [https://seekingalpha.com/symbol/DNA]) announced on Thursday that, in collaboration with Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT])-back... Full story

Yahoo Finance • 10 months ago

Robert A. Winn Excellence in Clinical Trials Award Program Announces 2025 Awardees for the Winn Career Development Award

The Winn Awards community welcomes 79 new physician-researchers from 23 states NORTHAMPTON, MA / ACCESS Newswire / November 12, 2025 / Originally published by The Robert A. Winn Excellence in Clinical Trials Award Program The Robert A. W... Full story

Yahoo Finance • 11 months ago

Ginkgo Bioworks Holdings Q3 Loss Widens

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA) on Thursday reported third-quarter net loss of $80.76 million or $1.45 per share, compared to $56.40 million or $1.08 per share in the comparable prior year period. Third-quarter total reve... Full story

Yahoo Finance • 11 months ago

Ginkgo Bioworks Holdings Q3 Earnings Preview

* Ginkgo Bioworks Holdings (DNA [https://seekingalpha.com/symbol/DNA]) is scheduled to announce Q3 earnings results on Thursday, November 6th, after market close. * The consensus EPS Estimate is -$1.24 [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • last year

Ginkgo Bioworks Holdings Inc (NYSE:DNA) Fits the Minervini Trend Template with Strong Technicals and High-Growth Momentum

Ginkgo Bioworks Holdings Inc (NYSE:DNA [https://www.chartmill.com/stock/quote/DNA]) has become a possible choice for investors using the Mark Minervini Trend Template and high-growth momentum strategies. The Minervini method blends strict... Full story

Yahoo Finance • last year

Ginkgo Bioworks launches cost-effective ADME profiling service

BOSTON - Ginkgo Bioworks (NYSE:DNA), a biotechnology company with a robust balance sheet showing a current ratio of 4.88x, announced on Thursday the introduction of a new high-throughput ADME profiling service aimed at accelerating small m... Full story

Yahoo Finance • last year

Is Ginkgo Bioworks Holdings, Inc. (DNA) the Best Gene-Editing Stock to Buy?

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best gene-editing stocks to buy. Gene editing is an ad... Full story

Yahoo Finance • 2 years ago

This 1 AI Stock Could Revolutionize Biotech and Pharma

Ginkgo Bioworks(NYSE: DNA) is a biotech that's going big on artificial intelligence (AI). Between its need to perform core workflows with high efficiency, and its generation of tons of biological and manufacturing data that demand analysis... Full story

Yahoo Finance • 2 years ago

Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE

Ginkgo's Class A Common Stock continues to trade on the NYSE BOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biose... Full story

Yahoo Finance • 3 years ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week

There never seems to be a bad time for Cathie Wood to reshape her portfolios. The founder, CEO, and main stock-picker for the Ark Invest family of exchange-traded funds has been busy adding to some of her positions this week. She has also... Full story

Yahoo Finance • 3 years ago

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Cathie Wood crushed it in 2023. Her flagship Ark Innovation ETF(NYSEMKT: ARKK) soared nearly 67%. The Ark Next Generation Internet ETF(NYSEMKT: ARKW) performed even better with an impressive 97% gain. If analysts are right, Wood could hav... Full story

Yahoo Finance • 3 years ago

2 Cathie Wood Stocks That Might Be Smart Buys Right Now

innovation Investors have shown a lot of interest in thematic exchange-traded funds (ETFs) since 2019. These funds focus on specific themes or sectors expected to grow rapidly in the future. One of the prominent players in this space is A... Full story

Yahoo Finance • 3 years ago

Ark Invest Stock Portfolio: 16 Biggest Positions

In this article, we discuss the 16 biggest positions in the ARK Invest portfolio. If you want to read about some more stocks in the ARK Invest portfolio, go directly to Ark Invest Stock Portfolio: 5 Biggest Positions. Catherine D. Wood, a... Full story